## Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>President’s Message</td>
<td>3</td>
</tr>
<tr>
<td>AMP Strategic Plan</td>
<td>4</td>
</tr>
<tr>
<td>Mission Statement</td>
<td>4</td>
</tr>
<tr>
<td>Vision Statement</td>
<td>5</td>
</tr>
<tr>
<td>Core Principles</td>
<td>5</td>
</tr>
<tr>
<td>2016 Board of Directors and Committee Chairs</td>
<td>6</td>
</tr>
<tr>
<td>International Affiliates</td>
<td>7</td>
</tr>
<tr>
<td>Organizational Relationships</td>
<td>7</td>
</tr>
<tr>
<td>Advocacy and Clinical Practice</td>
<td>8</td>
</tr>
<tr>
<td>Membership and AMP 2016 Annual Meeting Overview</td>
<td>9</td>
</tr>
<tr>
<td>International Education Initiatives</td>
<td>10</td>
</tr>
<tr>
<td>Financial Statement</td>
<td>11</td>
</tr>
</tbody>
</table>
Dear Colleagues,

The Association for Molecular Pathology is a diverse and dynamic community working to promote the highest quality molecular diagnostics and enhance patient care. We are molecular pathologists, clinical laboratorians, basic and translational scientists, technologists and trainees. While our members practice in various molecular diagnostics disciplines, we always find new ways to learn from each other and to broaden our scientific horizons.

As scientists, we recognize that collaboration and cooperation are essential to the advancement of our field. As a result, AMP is committed to fostering innovation and creating a welcoming environment for all. Whether you work in academic or community medical centers, government, or industry, I am delighted that you have chosen AMP as your professional home.

This has been a very busy year for our association. The AMP Annual Meeting remains the “premiere gathering” of molecular professionals and continues to grow in size and scope. We will also host our inaugural Global Congress next spring in Berlin, Germany. As technologies change and new challenges arise, our meetings, education resources, practice guidelines and advocacy efforts will continue to provide members and non-members alike with the critical information needed to remain at the cutting edge of our field and ensure that their patients receive the best results.

It has been my honor to serve as your President. I am proud of what we have accomplished together and I look forward to our continued successes.

Sincerely,

Charles E. Hill, MD, PhD
AMP President
Strategic Plan

MISSION • VISION • PRINCIPLES

AMP’S STRATEGIC PLAN IS DYNAMIC.

Implementation success is reviewed and celebrated annually by the Board of Directors, who add and archive strategic goals and objectives as necessary to accommodate the needs associated with this dynamic field. Foundational to its strategic plan are AMP’s Mission, Vision, and Core Principles.

MISSION STATEMENT

The ASSOCIATION FOR MOLECULAR PATHOLOGY is a not-for-profit scientific society that advances the CLINICAL PRACTICE, SCIENCE, and EXCELLENCE of molecular and genomic laboratory medicine through EDUCATION, INNOVATION, and ADVOCACY to enable highest quality health care.

I am A Molecular Professional…

“I want to use my scientific knowledge to help people.”

“I care about my patients and treat them in the way they deserve to be treated.”

“I can create something new and paradigm-shifting that had not existed.”

“I want to use my scientific knowledge to help people.”

“Personalized Medicine helps patients get the most effective treatments.”

“Little things can make a big difference for patients.”

Photos from “I am AMP (A Molecular Professional)” outreach campaign.

2016 Past President Janina A. Longtine, MD, Executive Director Mary Steele Williams, MNA, MT(ASCP)SM and former president Karen L. Kaul, MD, PhD pictured on Capitol Hill.
The ASSOCIATION FOR MOLECULAR PATHOLOGY seeks to be a global community of professionals that advances excellence in the clinical practice of molecular and genomic laboratory medicine through:

- Activities that foster INNOVATIVE and TRANSFORMATIVE PATIENT CARE and the translation of scientific discoveries into diagnostic tests and services
- EDUCATION PROGRAMS that promote clinical laboratory testing of high quality and utility
- ADVOCACY that supports the practice of molecular pathology to enhance patient care, addresses regulatory and payment issues, and facilitates the adoption of innovative laboratory testing and technologies
- Activities that facilitate knowledge transfer and COLLABORATION among professionals worldwide

CORE PRINCIPLES

- Quality Health Care Through EXCELLENCE in Clinical Molecular Testing
- Fostering the GLOBAL COMMUNITY of Molecular Pathology Professionals
- COLLABORATION to Advance Molecular Pathology
- ADVOCACY that Advances the Field and Practice of Molecular Pathology, Protects Patients, and Improves the Adoption of Innovative Technologies and Tests
- INNOVATION to Transform Patient Care

Eric S. Lander, PhD, recipient of the 2016 Award for Excellence in Molecular Diagnostics addresses the annual meeting audience.
2016 AMP Executive Committee: (l-r)
Siby Sebastian, PhD, Charles E. Hill, MD, PhD, Federico A. Monzon, MD, Janina A. Longtine, MD, Andrea Ferreira-Gonzalez, PhD

2016 AMP Board of Directors: (l-r)
Alexis B. Carter, MD, Charles E. Hill, MD, PhD, Siby Sebastian, PhD, Victoria M. Pratt, PhD, Janina A. Longtine, MD, Marina N. Nikiforova, MD, Jane Gibson, PhD, Samuel K. Caughron, MD, Nirali M. Patel, MD, Laura J. Tafe, MD, Andrea Ferreira-Gonzalez, PhD, Lei Po (Chris) Wong, PhD, Todd W. Kelley, MD, Frederico A. Monzon, MD, Roger D. Klein, MD, JD

2016  
BOARD OF DIRECTORS & COMMITTEE CHAIRS

CLINICAL PRACTICE COMMITTEE CHAIR (2015-2016)
Marina N. Nikiforova, MD
University of Pittsburgh Medical Center

ECONOMIC AFFAIRS COMMITTEE CHAIR (2016)
Samuel K. Caughron, MD
MAWD Pathology Group, PA

MEMBERSHIP AFFAIRS COMMITTEE CHAIR (2014-2016)
Nirali M. Patel, MD
UNC School of Medicine

PROFESSIONAL RELATIONS COMMITTEE CHAIR (2016)
Roger D. Klein, MD, JD
Roger D. Klein, MD, JD Consulting

PROGRAM COMMITTEE CHAIR (2016)
Victoria M. Pratt, PhD
Indiana University Medical Center

HEMATOPATHOLOGY SUBDIVISION CHAIR (2016-2017)
Todd W. Kelley, MD
University of Utah

INFORMATION SUBDIVISION CHAIR (2015-2016)
Alexis B. Carter, MD
Children's Healthcare of Atlanta

INFECTION DISEASES SUBDIVISION CHAIR (2015-2016)
Michael Lewinski, PhD
Roche Molecular Systems, Inc.

INFORMATICS SUBDIVISION CHAIR (2015-2016)
Alexis B. Carter, MD
Children's Healthcare of Atlanta

INVITED GUEST INTERNATIONAL AFFAIRS COMMITTEE CHAIR (2016)
Lei Po (Chris) Wong, PhD
University of Macau, Hong Kong

EXECUTIVE DIRECTOR
Mary Steele Williams, MNA, MT(ASCP)SM, CAE

PRESIDENT
Charles E. Hill, MD, PhD
Emory University School of Medicine

PRESIDENT-ELECT
And STRATEGIC OPPORTUNITIES COMMITTEE CHAIR (2016)
Federico A. Monzon, MD
Castle Biosciences

PAST PRESIDENT AND NOMINATING COMMITTEE CHAIR (2016)
Janina A. Longtine, MD
Yale School of Medicine/ Yale New Haven Hospital

SECRETARY-TREASURER AND FINANCE COMMITTEE CHAIR (2016-2017)
Andrea Ferreira-Gonzalez, PhD
Virginia Commonwealth University/ MCV Clinical Support Center

INFORMATIC SUBDIVISION
CHAIR (2016-2017)
Jane Gibson, PhD
University of Central Florida College of Medicine

TRAINING & EDUCATION COMMITTEE CHAIR (2016-2017)
Annette Kim, MD, PhD
Brigham and Women's Hospital

GENETICS SUBDIVISION CHAIR (2015-2016)
Siby Sebastian, PhD
Duke University Medical Center
INTERNATIONAL AFFILIATES

The Hong Kong Society for Molecular Diagnostic Sciences
The Korean Society for Laboratory Medicine
The Molecular Pathology Association of India
The German Society of Pathology

ORGANIZATIONAL RELATIONSHIPS

AMP maintains MEMBERSHIP in the following organizations:
Association of Pathology Chairs (APC) Pathology Roundtable
Cancer Leadership Council (CLC)
Federation of American Societies for Experimental Biology (FASEB)
Foundation for the National Institutes of Health Biomarkers Consortium
Global Alliance for Genomic Medicine
Inter-Society Coordinating Committee for Practitioner Education in Genomics (ISCC)
Intersociety Pathology Council (IPC)
Personalized Medicine Coalition (PMC)

AMP maintains productive organizational RELATIONSHIPS with the following groups:
Cooperating Society of the American Board of Pathology (ABP)
Steering Committee, NIST Genome in a Bottle Consortium
Associate Member of the Intersociety Council for Pathology Information (ICPI)
Sponsor of the National Academy of Medicine Roundtable on Genomics and Precision Health
Representative to the CAP Molecular Oncology Committee
Representative to the Pathology Coding Caucus
Liaison to/from the American Society of Cytopathology
Liaisons to/from many other professional societies on a project-specific basis

Expert Panelists from CAP, IASLC and AMP at the February 2016 working group meeting to revise the 2013 Lung Biomarker Guideline.
AMP ADVOCATES for excellence in molecular testing from the lab to the legislature. AMP’s advocacy efforts focus on advancing the field and practice of molecular pathology by informing and influencing public policy. AMP’s clinical and scientific affairs initiatives aim to transform patient care through INNOVATION.

ADVOCACY

In 2016, AMP launched The ChAMPion, a newsletter devoted exclusively to public policy topics, participated in several advocacy events, and issued 32 POSITION STATEMENTS and letters on issues such as:

- Reimbursement for Molecular Pathology and Genomic Sequencing Procedures
- Protecting Access to Medicare Act (PAMA)
- Local Coverage Determinations for Molecular Procedures
- Molecular Testing for Zika Virus
- Common Rule
- Proposed FDA Oversight of NGS-Based Diagnostics & LDPs
- Protecting the Genetic Information Nondiscrimination Act
- And Much More

INNOVATION & IMPROVED PATIENT CARE

In 2016, over 100 MEMBER VOLUNTEERS worked on multiple AMP efforts to foster excellence in clinical practice and patient care. These efforts included the launch of public open comment collection for the multidisciplinary lung cancer molecular biomarkers practice guideline and the publication of two major reports:

- The Spectrum of Clinical Utilities in Molecular Pathology Testing Procedures for Inherited Conditions and Cancer: A Report of the Association for Molecular Pathology

AMP ended the year with continued membership growth, rising from 2,354 in 2015 to 2,370 in 2016. Indicators suggest that the growth will continue for the coming years. AMP members can be found in 47 COUNTRIES.

Attendance continued to be strong at the 2016 ANNUAL MEETING. We welcomed over 2,000 attendees and approximately 1,800 exhibitors representing more than 200 companies.

<table>
<thead>
<tr>
<th>YEAR</th>
<th>LOCATION</th>
<th>SCIENTIFIC ATTENDEES</th>
</tr>
</thead>
<tbody>
<tr>
<td>2008</td>
<td>GAYLORD TEXAN, TX</td>
<td>969</td>
</tr>
<tr>
<td>2009</td>
<td>GAYLORD PALMS, FL</td>
<td>1,071</td>
</tr>
<tr>
<td>2010</td>
<td>SAN JOSE, CA</td>
<td>1,266</td>
</tr>
<tr>
<td>2011</td>
<td>GAYLORD TEXAN, TX</td>
<td>1,343</td>
</tr>
<tr>
<td>2012</td>
<td>LONG BEACH, CA</td>
<td>1,674</td>
</tr>
<tr>
<td>2013</td>
<td>PHOENIX, AZ</td>
<td>1,720</td>
</tr>
<tr>
<td>2014</td>
<td>WASHINGTON, DC</td>
<td>1,900</td>
</tr>
<tr>
<td>2015</td>
<td>AUSTIN, TX</td>
<td>2,059</td>
</tr>
<tr>
<td>2016</td>
<td>CHARLOTTE, NC</td>
<td>2,029</td>
</tr>
</tbody>
</table>

AMP members work in:

- Academic Medical Centers (42%)
- Commercial Reference Labs (12%)
- Community Hospital Labs (8%)
- Government (3%)
- NGOs (6%)
- Industry (21.5%)
- Other (7.5%)

AMP members by degree:

- PhD 854 (36%)
- MD 994 (42%)
- Other 522 (22%)
AMP's educational initiatives continue to reach a global audience. In 2016, AMP collaborated on molecular diagnostic-related conferences in Chandigarh, India; Seoul, Korea; and Montesilvano, Italy.

AMP hosted its second International Showcase event at the AMP 2016 Annual Meeting. In addition, the inaugural 2017 Global Congress on Molecular Pathology will be held in Berlin, Germany, April 3-5, 2017.
AMP’s fiscal footing is solid, allowing it to dedicate significant resources to each of its strategic initiatives.

<table>
<thead>
<tr>
<th>STRATEGIC INITIATIVE</th>
<th>2016</th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advocacy</td>
<td>$(426,435)</td>
<td>$(425,166)</td>
<td>$(586,685)</td>
</tr>
<tr>
<td>Communications &amp; Outreach</td>
<td>$(174,649)</td>
<td>$(206,633)</td>
<td>$(183,330)</td>
</tr>
<tr>
<td>Education</td>
<td>$2,299,693</td>
<td>$2,800,434</td>
<td>$1,985,130</td>
</tr>
<tr>
<td>Innovation &amp; Improved Patient Care</td>
<td>$(290,237)</td>
<td>$(280,556)</td>
<td>$(250,085)</td>
</tr>
<tr>
<td>Membership &amp; Management Services</td>
<td>$(32,781)</td>
<td>$(502,766)</td>
<td>$(573,771)</td>
</tr>
</tbody>
</table>

| EXCESS REVENUE OVER EXPENSES                  | $1,375,591   | $1,385,313   | $391,259     |